Hira Mian: Canadian consensus guidelines on MRD testing
Hira Mian, Hematology oncologist at Hamilton Health Sciences, posted on X about recent paper he co-authored with colleagues, titled “Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada” published on Clinical Lymphoma, Myeloma and Leukemia.
Authors: Hira S Mian, Alissa Visram, Steven Chun-Min Shih, Suzanne Trudel, Annette E Hay, Richard LeBlanc, Michael Sebag, Rayan Kaedbey, Julie Stakiw, Irwindeep Sandhu, Chai W Phua, Philip G Kuruvilla, Ibraheem Othman, Graeme Quest, David McMullen, Gabriele Colasurdo, Rami Kotb, Christopher P Venner
“Canadian consensus guidelines on MRD testing in Canada…Bottom line: we need access to publicly funded MRD testing for our MM patients across Canada.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023